Who are Capecitabine combined with Pyrotinib's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/capecitabine-combined-with-pyrotinib.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Capecitabine combined with Pyrotinib — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Capecitabine combined with Pyrotinib (Capecitabine combined with Pyrotinib) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination chemotherapy and tyrosine kinase inhibitor. Area: Oncology.

phase 3 Combination chemotherapy and tyrosine kinase inhibitor Thymidylate synthase (capecitabine); HER1/EGFR, HER2, HER4 (pyrotinib) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Capecitabine combined with Pyrotinib (Capecitabine combined with Pyrotinib) — Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University. Capecitabine is a prodrug that converts to 5-fluorouracil to inhibit thymidylate synthase, while pyrotinib is a pan-HER tyrosine kinase inhibitor that blocks HER1, HER2, and HER4 signaling.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Capecitabine combined with Pyrotinib TARGET	Capecitabine combined with Pyrotinib	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	phase 3	Combination chemotherapy and tyrosine kinase inhibitor	Thymidylate synthase (capecitabine); HER1/EGFR, HER2, HER4 (pyrotinib)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination chemotherapy and tyrosine kinase inhibitor class)

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Capecitabine combined with Pyrotinib — Competitive Intelligence Brief. https://druglandscape.com/ci/capecitabine-combined-with-pyrotinib. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab